INTRODUCTION Infections associated with medical devices are often related to colonization by Candida spp. biofilm; in this way, numerous strategies have been developed and studied, mainly in order to prevent this type of fungal growth. AIM Considering the above, the main objective of the present study is to make a rational choice of the best antifungal therapy for the in vitro treatment of the biofilm on venous catheters, proposing an innovative formulation of a film-forming system to coat the surface in order to prevent the formation of biofilms. METHODOLOGY Anidulafungin, fluconazole, voriconazole, ketoconazole, amphotericin B, and the association of anidulafungin and amphotericin B were tested against biofilms of C. albicans, C. tropicalis, and C. parapsilosis strains in microtiter plates and in a polyurethane catheter. Besides, anidulafungin, amphotericin B, and the combination of both were incorporated in a film-forming system and were evaluated against biofilm. RESULTS The superior activity of anidulafungin was demonstrated in relation to the other antifungal agents. Although amphotericin B showed good activity, high concentrations were required. The combination showed a synergistic action, in solution and in the formulation, showing excellent results, with activity above 90%. CONCLUSION Due to the superiority of anidulafungin and the synergistic activity of the combination, these alternatives were the most promising options for use in a formulation proposal as a new strategy to combat the Candida spp. biofilm. These formulations demonstrated high in vitro performance in the prevention of biofilms, indicating that they are candidates with great potential for in vivo tests.

中文翻译：

---

合理选择抗真菌药物提出控制静脉导管念珠菌生物膜形成的新配方策略

简介 与医疗器械相关的感染通常与念珠菌定植有关。生物膜；通过这种方式，已经开发和研究了许多策略，主要是为了防止这种真菌的生长。目的 考虑到上述情况，本研究的主要目的是合理选择体外治疗静脉导管上生物膜的最佳抗真菌治疗方法，提出一种创新的成膜系统配方，将表面覆盖在以防止生物膜的形成。方法学 在微量滴定板和聚氨酯导管中，针对白色念珠菌、热带念珠菌和近平滑念珠菌菌株的生物膜对阿尼芬净、氟康唑、伏立康​​唑、酮康唑、两性霉素 B 以及阿尼芬净和两性霉素 B 的联合进行了测试。此外，阿尼芬净，两性霉素 B 和两者的组合被纳入成膜系统，并针对生物膜进行评估。结果 与其他抗真菌剂相比，阿尼芬净的活性更高。尽管两性霉素 B 显示出良好的活性，但仍需要高浓度。该组合在溶液和制剂中显示出协同作用，显示出优异的结果，活性超过 90%。结论 由于阿尼芬净的优越性和组合的协同活性，这些替代品是最有希望用于制剂提案的选择，作为对抗念珠菌属的新策略。生物膜。这些制剂在预防生物膜方面表现出很高的体外性能，表明它们是具有巨大体内试验潜力的候选物。